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Short Communication
Cystic fluid-platinum kinetics in ovarian cancer patients:
Relevance to cis-dichlorodianmine platinum (II) sensitivity
testing in vitro
M.D. Shelley, R.G. Fish, M. Adams & I. Kerby
South Wales Raotherapy and Oncology Service, Velinde Hospital, Whitchurch, CardiffCF4 7XL
Intravenous administration of the anticancer drug,
cis-dichlorodimmineplatinum (CDDP) leads to
tumour regression in 50% of patients with
advanced ovarian cancer (Gershenson et al, 1981;
Adams et al, 1984). The number of treatment
failures, coupled with the drug-induced host
toxicities in this condition, have prompted studies
on the human tumour stem cell assay (Salmon &
Von Hoff; 1982) in which CDDP, or other cytotoxic
agents, are incubated with cultured biopsy material
and the extent ofcell kill in vitro used to predt the
sensitivity of an individual patient's tumour to the
drug. The potential clinical usefulness of this test
has been discussed (Von Hoff, 1983) and a number
of practial problems assocated with the assay
have been described (Von Hoff & Weisenthall,
1980). One difficulty concerns the lack of precise
knowledge on the interpatient variability of CDDP
levels surrounding tumour cells, and has led to the
use of a wide range of drug concentrations and
exposure times for sensitivity testing in vitro
(Alberts et al., 1981; Wilson & Neal, 1981; Morasca
et al., 1983). For this reason we have studied the
time-course of both total and non-protein bound
(ultrafilterable) platinum in plasma and the cystic
fluid associated with tumour cells in patients with
cystadenocarcinoma of the ovary receiving i.v.
infusions of CDDP. The results show that tumour
exposure to total drug concentration in this
condition is variable between patients and it is
suggested that the availability of potentially active
platinum species is less than was often previously
anticipated.
Three patients were diagnosed at primary laparo-
tomy as having Stage l, cystadenocarcnoma
of the ovary. They had a tumour burden >Ocm
in diameter and multiple peritoneal metastases were
present. Debulking of the tumour mass was not
feasible. The malignant cysts were multilocular with
solid tumour elements and consequently it was not
possible to obtain meaningful estimates of total
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cystic fluid volume. Approximately 4 weeks after
the primary surgery, the 3 patients were given a
6h i.v. infusion of CDDP. Before drug therapy,
serum urea, creatinine, eklctrolytes and birubin were
within the normal range. Twenty-four hours prior
to, and following CDDP infusion, 21 respectively
of 5% dextrose-normal saline and normal saline
were admini i.v. A bolus of mannitol (12.5g)
was given immiately before CDDP. The cyto-
toxic drug was admini in 21 of normal saline
containing 25g ofmannitol.
Plasma samples were taken at intervals for 24h
after the initiation of drug therapy. Fluid from
within the malignant cyst was aspirated under local
anesthetic using a 21 gauge needle. Collctions of
cystic fluid were obtained before, during, at the end
of CDDP therapy and post-infusion at 3 and 24h.
Aliquots of plasma and cystic fluid were im-
fmdiately ultrafiltered by means of Amicon
Centriflo CF 25 cones. The ultrafiltrates were used
for the determination of the free (non-protein
bound) platinum concentrations. The orginal
plasma, cystic fluids and ultrafiltrates were stored
at -20°C before analysis. Platinum levels were
measured by flamekss atomic absorption spectro-
photometry as descnbed previously (FLsh et al.,
1984). Plasma and cystic fluid samples containing
CDDP were evaluated using pre-infusion fluids
spiked with drug, to overcome any matrix inter-
ference. The area under the concentration x
time curve (AUC) for platinum in plasma and cystic
fluid was measured by the trapezoidal method.
The time-course of total platinum in plasma and
cystic fluid for the three patients is shown in Figure
1. In both fluids, peak platinum levels occurred at
the end of drug infusion, and after 24h, the total
plasma platinum level had fallen to -80% of the
peak values. The maximum total platinum
concentration achieved and the calclated AUCs in
cystic fluid were variable between patients (Table X).
It is known that CDDP or its metabolites bind
firmly to plasma proteins (Vermorken et al., 1984).
These macromolecular complexes appear to have
little demonstrable cytotoxicity in vitro (Holdener et
al., 1983) and therefore, it would seem that the
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Fugwe 1 Concentration of total platinum in plasma
(0) and cystic fluid (0) in patients A, B and C
receiving a 6h i.v. infusion ofCDDP (-).
Table I Platinum concentration in cystic fluid and plasma
from three patients
Patients
Parameter A B C
Dose (mgm-2) 100 60 60
Peak concentration (gml-1)
Plasma, total platinum 3.01 2.50 2-28
Cystic, total platinum 1.72 1.50 0.41
Plasma, ultrafilterable platinum 0.41 0.38 0.48
Cystic, ultrafilterable platinum 0.38 0.44 0.35
AUCo 2,4gMl - 1h)
Plasma, total platinum 50.07 43.40 35.60
Cystic, total platinum 25.77 21.60 5.80
Plasma, ultrafilterable platinum 207 220 3.10
Cystic, ultrafilterable platinum 1.15 1.50 1.60
direct use of pharmacokinetic data based upon the
total achievable plasma platinum levels in patients
is inappropriate as a reflection of tumour exposure
to active platinum species.
The mean concentration changes for the non-
protein bound platinum species in the 3 patients are
0.02
Time (h)
Figwe 2 Mean concentrations (+ s.e.) of non-protein
bound (ultrafilterable) platinum in plasma (0) and
cystic fluid (0) in 3 patients receiving CDDP (-).
shown in Figure 2. Peak platinum levels were
similar in both fluids and between patients. The
AUCs for ultrafilterable platinum in the cystic
fluids were -50% of those for plasma (Table I),
although more frequent sampling of this fluid may
have provided a better estimate. In both fluids, the
non-protein bound platinum declined rapidly
during the post-infusion period and was below
detection after 3h.
In these patients, platinum species rapidly
diffused into cystic fluid and, with the present
dosing schedule, peak levels ranging from 0.38-
0.48 ugml-1 and a tumour exposure (AUC) of
1.15-1.60pgmlI-h-1 were obtained for the
pharmacologically active non-protein bound
platinum in this fluid. It is concluded that the free
platinum concentration is similar in the cystic fluid
of all 3 patients, as is that in the plasma. The data
support the idea of using only 10% of the peak
plasma concentration of total platinum as a
reasonable in vitro assay concentration (Alberts et
al, 1981).
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